Ronald Barke, MD
Ophthalmology · Arlington, TXNPI 1447255476
Payments from drug & device makers
Across 262 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$1K
- Bausch & Lomb Americas Inc.$438
- Notal Vision, Inc.$352
- Ocular Therapeutix, Inc.$345
- Bausch & Lomb, A Division Of Bausch Health US, LLC$318
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$3776%
- Food & beverage$5,60692%
- Other$1182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 80 | $1,644 |
| AbbVie(2 entities) | 52 | $1,104 |
| Bausch & Lomb Americas Inc. | 23 | $438 |
| Notal Vision, Inc. | 1 | $352 |
| Ocular Therapeutix, Inc. | 18 | $345 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $318 |
| Carl Zeiss Meditec, Inc. | 2 | $249 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $213 |
| Sight Sciences, Inc. | 9 | $166 |
| Aerie Pharmaceuticals, Inc. | 8 | $161 |
| Alcon Research LLC | 1 | $134 |
| Rxsight Inc | 6 | $130 |
| Novartis | 7 | $130 |
| Glaukos Corporation | 7 | $128 |
| Halozyme Inc | 3 | $105 |
| Oyster Point Pharma, Inc. | 3 | $72 |
| Eyevance Pharmaceuticals LLC | 4 | $65 |
| Optos, Inc. | 2 | $56 |
| Tarsus Pharmaceuticals, Inc. | 2 | $48 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Harrow Eye, LLC | 2 | $40 |
| Astellas Pharma US Inc | 1 | $29 |
| Ivantis, Inc | 1 | $25 |
| Dompe US, Inc. | 1 | $25 |
| Tearlab Corp | 2 | $21 |
| Coopervision Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Akorn, Inc. | 1 | $14 |
| Lumenis, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,102 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 160 | $86,176 |
| RestasisCyclosporine | 22 | $30,043 |
| RocklatanNetarsudil Mesylat/Latanoprost | 46 | $25,685 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 145 | $22,803 |
| CombiganBrimonidine Tartrate/Timolol | 61 | $21,899 |
| VyzultaLatanoprostene Bunod | 22 | $10,026 |
| Cyclosporine | 13 | $9,823 |
| Travoprost | 56 | $8,153 |
| Latanoprost | 580 | $7,099 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $6,235 |
| Prednisolone Acetate | 116 | $5,204 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 217 | $3,995 |
| Timolol Maleate | 181 | $3,567 |
| MoxifloxacinMoxifloxacin Hcl | 132 | $3,371 |
| TobradexTobramycin/Dexamethasone | 11 | $2,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $1,104 | $138,119243 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $161 | $25,68546 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $438 | $10,02622 claims |
| AlconSimbrinza | $1,644 | $6,23525 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $318 | $1,47811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Arlington
- Patrick WilliamsArlington$6.6M
- David CallananArlington$2.1M
- Wayne SolleyArlington$1.5M
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Ashkan AbbeyDallas$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.